Enabling technologies for Human Papillomavirus vaccination in girls aged 9 to 17 years in Colombia - Huila Pilot

Project: Research Project

Project Details


Human Papillomavirus (HPV) is a group of circular DNA viruses that cause various manifestations in people, mainly women, characterised by skin lesions and the possible development of malignant lesions framed in different types of cancer, the most common being cervical cancer (1). In Colombia, cervical cancer has an incidence rate of 18.3 per 100,000 women per year and a mortality rate of 9.61. Population-based studies have found that women diagnosed with this type of cancer are increasingly younger, have fewer economic resources and live in rural areas (2).
Vaccination against HPV helps prevent the development of this type of malignant pathology and has led the World Health Organisation (WHO) to make a public health effort to meet its 2030 objective: 90% of girls vaccinated by the age of 15, 70% of women screened at 35 and 45 years of age, and 90% of women diagnosed with precancer and invasive cancer undergoing timely treatment (2).
Colombia was one of the first countries in the region to implement the vaccination strategy in 2012, reaching targets of 97.9% and 94.8% of the target population with one and two doses of vaccination respectively, however, in 2014 a group of young women in a coastal municipality of the country presented episodes of collective psychogenic response, which generated fear and misinformation in the population leading to a decrease in vaccination to 6.1% in 2016. This vaccination coverage has increased to 39.4% in 2021, but has not reached the targets proposed by the WHO and poses a higher risk for the development of cervical cancer in the Colombian population (2).
Among the main barriers identified that decrease the vaccination coverage of women is a pillar of health education, focused on the safety of the vaccine and lack of information (2), and, on the other hand, the completion of the physical informed consent that has meant a barrier because parents and/or caregivers do not fill it out in the corresponding times, they get lost, and generate paper waste affecting the environment.
It is for this reason that our Technological Development Project, starting with a pilot project in Huila, within the framework of the Human Papillary Virus (HPV)
Huila, within the framework of the Vaccination against Human Papillary Virus (HPV) is a solution that will allow us to respond to a problem experienced by women in the region, where coverage rates are low.
to respond to a problem experienced by women in the region, where coverage rates are the lowest in the country.
the lowest coverage rates in the country, by means of a joint construction approach between researchers and the community, with a
community towards the contribution from a technical, social, environmental and economic dimension that will make the Universidad del Rosario and Colombia a reference and will allow the replicability of this project in similar contexts.
similar contexts.


Human papillomavirus; Papillomavirus vaccines; Health Education; Science, Technology & Society; Health
Health; Science, Technology and Society
Effective start/end date11/22/2311/22/24

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Main Funding Source

  • Installed Capacity (Academic Unit)


  • Huila


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.